These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 36709185)
1. [Bendamustine monotherapy for Chinese patient treatment with relapsed or refractory B cell non-Hodgkin lymphoma: a phase Ⅱ, prospective, multicenter, single-arm study]. Gao Y; Yang Y; Cen H; Liu H; Fu JX; Wang SQ; Feng R; Yu D; Zhang XY; Chen ZW; Li YF; Huang HQ Zhonghua Xue Ye Xue Za Zhi; 2022 Nov; 43(11):934-939. PubMed ID: 36709185 [No Abstract] [Full Text] [Related]
2. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Ohmachi K; Ando K; Ogura M; Uchida T; Itoh K; Kubota N; Ishizawa K; Yamamoto J; Watanabe T; Uike N; Choi I; Terui Y; Usuki K; Nagai H; Uoshima N; Tobinai K; Cancer Sci; 2010 Sep; 101(9):2059-64. PubMed ID: 20626754 [TBL] [Abstract][Full Text] [Related]
3. Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China. Gao Y; Liu Y; Wang Y; Zhang Q; Wu D; Ye X; Wu J; Xu W; Zhou J; Yang Y; Cen H; Zhang F; Xiang Y; Tang X; Ding K; Lin J; Ma L; Wang S; Yu H; Zhao Y; Song B; Lv F; Huang H Cancer; 2023 Feb; 129(4):551-559. PubMed ID: 36541221 [TBL] [Abstract][Full Text] [Related]
4. Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study. Shi YK; Hong XN; Yang JL; Xu W; Huang HQ; Xiao XB; Zhu J; Zhou DB; Han XH; Wu JQ; Zhang MZ; Jin J; Ke XY; Li W; Wu DP; Yang SM; Du X; Jia YQ; Liu AC; Liu DH; Shen ZX; Zhang LS; James L; Hellriegel E Chin Med J (Engl); 2021 May; 134(11):1299-1309. PubMed ID: 33967195 [TBL] [Abstract][Full Text] [Related]
6. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis. Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160 [TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of bendamustine-rituximab combination therapy for newly diagnosed indolent B-cell non-Hodgkin's lymphoma and elderly mantle cell lymphoma: a multi-center prospective phase II clinical trial in China]. Wang H; He Q; Liu D; Deng XZ; Ma J; Xie LN; Sun ZL; Liu C; Zhao RR; Lu K; Chu XX; Gao N; Wei HC; Sun YH; Zhong YP; Xing LJ; Zhang HY; Zhang H; Xu WW; Li ZJ Zhonghua Xue Ye Xue Za Zhi; 2023 Jul; 44(7):550-554. PubMed ID: 37749033 [No Abstract] [Full Text] [Related]
8. Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study. Sakai R; Ohmachi K; Sano F; Watanabe R; Takahashi H; Takasaki H; Tanaka M; Hattori Y; Kimura H; Takimoto M; Tachibana T; Tanaka E; Ishii Y; Ishiyama Y; Hagihara M; Miyazaki K; Yamamoto K; Tomita N; Ando K Ann Hematol; 2019 Sep; 98(9):2131-2138. PubMed ID: 31286196 [TBL] [Abstract][Full Text] [Related]
9. Bendamustine Plus Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Low-grade B-cell Lymphoma and Mantle Cell Lymphoma: A Single-Center Retrospective Study. Murakami H; Yoshioka T; Moriyama T; Ishikawa T; Makita M; Sunami K Acta Med Okayama; 2021 Aug; 75(4):461-469. PubMed ID: 34511613 [TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Ogura M; Uchida T; Taniwaki M; Ando K; Watanabe T; Kasai M; Matsumoto Y; Shimizu D; Ogawa Y; Ohmachi K; Yokoyama H; Tobinai K; Cancer Sci; 2010 Sep; 101(9):2054-8. PubMed ID: 20594195 [TBL] [Abstract][Full Text] [Related]
11. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. de Vos S; Swinnen LJ; Wang D; Reid E; Fowler N; Cordero J; Dunbar M; Enschede SH; Nolan C; Petrich AM; Ross JA; Salem AH; Verdugo M; Agarwal S; Zhou L; Kozloff M; Nastoupil LJ; Flowers CR Ann Oncol; 2018 Sep; 29(9):1932-1938. PubMed ID: 30060083 [TBL] [Abstract][Full Text] [Related]
12. Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan. Ogura M; Ishizawa K; Maruyama D; Uike N; Ando K; Izutsu K; Terui Y; Imaizumi Y; Tsukasaki K; Suzuki K; Izumi T; Usuki K; Kinoshita T; Taniwaki M; Uoshima N; Suzumiya J; Kurosawa M; Nagai H; Uchida T; Fukuhara N; Choi I; Ohmachi K; Yamamoto G; Tobinai K; Int J Hematol; 2017 Apr; 105(4):470-477. PubMed ID: 27900638 [TBL] [Abstract][Full Text] [Related]
13. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M; Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421 [TBL] [Abstract][Full Text] [Related]
14. Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Heyman B; Rizzieri D; Adams DJ; De Castro C; Diehl L; Li Z; Moore J; Beaven A Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):679-686. PubMed ID: 30166257 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials. Wang J; Zhou H; Mu M; Zhao A; Cai Z; Li L; Wang M; Niu T Front Immunol; 2022; 13():1034253. PubMed ID: 36439091 [TBL] [Abstract][Full Text] [Related]
16. A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study. Matsumoto K; Takayama N; Aisa Y; Ueno H; Hagihara M; Watanabe K; Nakaya A; Chen K; Shimizu T; Tsukada Y; Yamada Y; Nakazato T; Ishida A; Miyakawa Y; Yokoyama K; Nakajima H; Masuda Y; Yano T; Okamoto S; Int J Hematol; 2015 Jun; 101(6):554-62. PubMed ID: 25783753 [TBL] [Abstract][Full Text] [Related]
17. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Kahl BS; Bartlett NL; Leonard JP; Chen L; Ganjoo K; Williams ME; Czuczman MS; Robinson KS; Joyce R; van der Jagt RH; Cheson BD Cancer; 2010 Jan; 116(1):106-14. PubMed ID: 19890959 [TBL] [Abstract][Full Text] [Related]
18. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Dennie TW; Kolesar JM Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042 [TBL] [Abstract][Full Text] [Related]
19. Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia. Flinn IW; Cherry MA; Maris MB; Matous JV; Berdeja JG; Patel M Am J Hematol; 2019 Dec; 94(12):1325-1334. PubMed ID: 31490009 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Hsiao LT; Tien HF; Kuo CY; Wu JH; Hou HA; Wang MC; Liu CY; Chen PM; Chiou TJ Hematol Oncol; 2015 Dec; 33(4):136-44. PubMed ID: 25111959 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]